On 21 August 2019, orphan designation EU/3/19/2192 was granted by the European Commission to TMC Pharma (EU) Limited, Ireland, for setmelanotide for the treatment of Bardet Biedl syndrome.
The sponsorship was transferred to Rhythm Pharmaceuticals Limited, Ireland, in November 2020.
|Disease / condition||
Treatment of Bardet-Biedl syndrome
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: